Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.08+0.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ENTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -54.8% |
| Our one-year growth estimate | diamond | -2.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ENTA — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Why it matters: Positive cash flow would show that Enanta is moving towards financial stability. This is crucial for its long-term success.
Supportive ifCash flow from operations turns positive in Q2 2026.
Worry ifCash flow from operations remains negative or worsens in Q2 2026.
Why it matters: The result could affect Enanta's finances. It may impact their ability to make money from their IP.
Watch forA good ruling in the patent case against Pfizer about PAXLOVID.
Also watch forA bad ruling could limit Enanta's claims or the money they can get.
Why it matters: Higher operating income shows better financial health and performance. This can bring in more investors.
Supportive ifOperating income in Q2 2026 is less negative than -$11.85M.
Worry ifOperating income in Q2 2026 worsens beyond -$11.85M.
Why it matters: A smaller net loss shows better cost control and efficiency. This helps investors feel confident.
Supportive ifNet loss in Q2 2026 is less than $13.1M.
Worry ifNet loss in Q2 2026 increases beyond $13.1M.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $501 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,430 loss on $10,000 · 34.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This data will show if zelicapavir works for high-risk adults with RSV. Good results could help it get approved.
Supportive ifData from the Phase 2b/3 trial shows big improvement in RSV symptoms in high-risk adults.
Worry ifData does not show big improvement in RSV symptoms compared to placebo.
Why it matters: Filing an IND for EPS-3903 is a key step in advancing Enanta's immunology pipeline. It could lead to new treatment options.
Supportive ifEnanta files the IND for EPS-3903 as planned in the second half of 2026.
Worry ifThe IND filing for EPS-3903 is delayed or not submitted as expected.
Why it matters: Filing an IND would help Enanta's immunology work. It shows they are making progress.
Supportive ifSuccessful filing of an IND for EPS-3903 with the FDA.
Worry ifFailure to file the IND or delays in the process.
Why it matters: Watching cash burn is key to knowing Enanta's financial health. It shows their ability to fund operations.
Worry ifCash burn rate is lower than in past quarters. This shows better financial management.
Less concerning ifCash burn rate is rising. This raises worries about how long they can keep funding.
Why it matters: The result could change Enanta's finances. It might also affect their ability to run operations.
Watch forThe court rules in favor of Enanta. This supports their patent claims against Pfizer.
Also watch forThe court rules against Enanta. This weakens their patent position and may lower revenue.
Why it matters: Starting this trial is key for advancing treatment for high-risk adults with RSV. It could lead to the first approved antiviral for RSV.
Supportive ifThe Phase 2b/3 trial of zelicapavir in high-risk adults begins as planned in Q4 2026.
Worry ifThe trial is now delayed past Q4 2026. This shows there may be problems in development.
Why it matters: Topline data will show how well EDP-978 works for chronic urticaria. This data can impact the immunology pipeline's value.
Supportive ifTopline data from the Phase 1 trial of EDP-978 is reported in 4Q 2026.
Worry ifNo data is reported or delays are announced beyond 4Q 2026.
Why it matters: Starting this trial is key for advancing treatment for high-risk adults with RSV. It can validate the drug's potential.
Supportive ifThe RESOLVE trial of zelicapavir begins in 4Q 2026.
Worry ifThe trial does not start as planned in 4Q 2026.
Why it matters: Data from this trial will show how effective zelicapavir is for children with RSV. It can impact future treatment options.
Supportive ifTopline data from the pediatric Phase 2b trial is reported in 2027.
Worry ifNo data is reported or delays are announced beyond 2027.